Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Прижизненное донорство почки

Cписок литературы

  1. Данович ГМ. Трансплантация почки. М: ГЭОТАР-Медиа; 2013: 848.
  2. Федеральный закон от 21.11.2011 N 323-ФЗ (ред. от 29.05.2019) "Об основах охраны здоровья граждан в Российской Федерации". Статья 47. Донорство органов и тканей человека и их трансплантация (пересадка).
  3. Fresenius medical care annual report 2018; 2018.
  4. Андрусев АМ, Томилина НА, Перегудова НГ, Шинкарев МБ. 3аместительная терапия терминальной хронической почечной недостаточности в Российской Федерации 2014-2018 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества; 2019.
  5. Готье СВ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2019 году. XII сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2020; 22(2): 8-34.
  6. Закон РФ от 22.12.1992 N 4180-1 ред. от 29.11.2007 «О трансплантации органов и (или) тканей человека».
  7. Englum BR, Schechter MA, Irish WD, et al. Outcomes in kidney transplant recipients from older living donors. Transplantation 2015; 99: 309-15.
  8. Oien CM, Reisæter AV, Leivestad T, Dekker FW, Line PD, Os I. Living donor kidney transplantation: the effects of donor age and gender on short- and longterm outcomes. Transplantation 2007; 83: 600-6.
  9. Hawley CM, Kearsley J, Campbell SB, et al. Estimated donor glomerular filtration rate is the most important donor characteristic predicting graft function in recipients of kidneys from live donors. Transpl Int 2007; 20: 64-72.
  10. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017; 101, N8S-1: 1–106.
  11. Thiessen C, Gordon EJ, Reese PP, et al. Development of a donor- centered approach to risk assessment: rebalancing nonmaleficence and autonomy. Am J Transplant. 2015; 15: 2314–2323.
  12. Delmonico F, Council of the Transplantation Society. A report of the Amsterdam forum on the care of the live kidney donor: data and medical guidelines. Transplantation. 2005; 79 (6 Suppl): S53–S66.
  13. British Transplantation Society / Renal Association UK Guidelines for Living Donor Kidney Transplantation 2018. https://bts.org.uk/wp- content/uploads/2018/07/FINAL_LDKT-guidelines_June-2018.pdf

  1. ОPTN (Organ Procurement and Transplantation Network)/UNOS (United Network for Organ Sharing). OPTN Policies, Policy 14: Living Donation. http://optn.transplant.hrsa.gov/governance/policies/. (Accessed: June 28, 2017).
  2. Cancer Research UK: Cancer Incidence by Age: 2012-2014. http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age - heading- Zero.
  3. Fehrman-Ekholm I, Gabel H, Magnusson G. Reasons for not accepting living kidney donors. Transplantation 1996; 61: 1264-5.
  4. Young A, Karpinski M, Treleaven D, et al. Differences in tolerance for health risk to the living donor among potential donors, recipients, and transplant professionals. Kidney Int 2008; 73: 1159-66.
  5. International Diabetes Federation: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. World Health Organisation (WHO); 2006.
  6. Tydén G, Kumlien G, Berg UB. ABO-incompatible kidney transplantation in children. Pediatr Transplant. 2011; 15(5): 502-4.
  7. Hourmant M, Figueres L, Gicquel A, et al. New rules of ABO-compatibility in kidney transplantation. Transfus Clin Biol. 2019; 26(3): 180-183.
  8. Shaw C, Sharp CC. Could sickle cell trait be a predisposing risk factor for CKD? Nephrol Dial Transplant 2010; 25: 2403-5.
  9. RP Naik, VK Derebail, ME Grams, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 2014; 312: 2115-25.
  10. Reese PP, Hoo AC, Magee CC. Screening for sickle trait among potential live kidney donors: policies and practices in US transplant centers. Transpl Int 2008; 21: 328-31.
  11. Cetin T, Oktenli C, Ozgurtas T, et al. Renal tubular dysfunction in betathalassemia minor. Am J Kidney Dis 2003; 42: 1164-8.
  12. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология, 2015; 9 (2): 4-46.
  13. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e326-50.
  14. Fenton A., Montgomery E., Nightingale P., Peters A.M., Sheerin N., Wroe A.C., Lipkin G.W. Glomerular filtration rate: new age- and gender- specific reference ranges and thresholds for living kidney donation. BMC Nephrol. 2018; 19: 336. doi: 10.1186/s12882-018- 1126-8.
  15. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-74.
  16. Halbesma N, Kuiken DS, Brantsma AH, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006; 17: 2582-90.
  17. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32.
  18. Wise GJ, Schlegel PN. Sterile pyuria. N Engl J Med 2015; 372: 1048-54.
  19. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.
  20. AUA Guidelines 2020: Microhematuria. https://www.urotoday.com/conference- highlights/aua-2020/aua-2020-bladder-health/122536-aua-guidelines-2020-microhematuria.html
  21. Mohr DN, Offord KP, Owen RA, Melton LJ. Asymptomatic microhematuria andurologic disease: a population based study. JAMA 1986; 256: 224-9.
  22. Vivante A, Afek A, Frenkel-Nir Y, et al. Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for endstage renal disease. JAMA 2011; 306: 729-36.
  23. Yamagata K, Kobayashi M, Koyama A. A long-term follow up study of asymptomatic haematuria and/or proteinuria in adults. Clin Nephrol 1996; 45: 281-8.
  24. Jaffe JS, Ginsberg PC, Gill R, Harkaway RC. A new diagnostic algorithm for the evaluation of microscopic haematuria. Urology 2001; 57: 889-94.
  25. Koushik R, Garvey C, Manivel C, Matas AJ, Kasiske B. Persistent, asymptomatic microscopic hematuria in prospective kidney donors. Transplantation 2005; 80: 1425-9.
  26. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with haematuria to evaluate current diagnostic practice. J Urol 2000; 163: 524-7.
  27. Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol- driven haematuria clinic. BJU Int 2006; 97: 301-5.
  28. Постановление Правительства РФ от 22.06.2019 N 797 «Об утверждении Правил заготовки, хранения, транспортировки и клинического использования донорской крови и ее компонентов и о признании утратившими силу некоторых актов Правительства Российской Федерации».
  29. Guidance on microbiological safety of human organs, tissues and cells used in transplantation. Advisory Committee on the Safety of Blood Tissues and Organs (SaBTO); 2018.
  30. Van Son WJ, The TH. Cytomegalovirus infection after organ transplantation: an update with special emphasis on renal transplantation. Transpl Int 1989; 2: 147-64.
  31. Cook RI, Wreathall J, Smith A, et al. Probabilistic risk assessment of accidental ABO-incompatible thoracic organ transplantation before and after 2003. Transplantation. 2007; 84: 1602–1609.
  32. Montgomery JR, Berger JC, Warren DS, et al. Outcomes of ABO- incompatible kidney transplantation in the United States. Transplantation. 2012; 93: 603–609.
  33. Tait BD, S sal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA an- tibodies in transplantation. Transplantation. 2013; 95(1): 19-47.
  34. Lobashevsky AL, Higgins NG, Rosner Kevin M, et al. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Transplantation. 2013; 96(2): 182-90.
  35. Taylor CJ, Kosmoliaptsis V, Summers DM, Bradley JA. Back to the future: application of contemporary technology to longstanding questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Human Immunol 2009; 70: 563-8.
  36. Opelz G. Impact of HLA compatibility on survival of kidney transplants from unrelated live donors. Transplantation 1997; 64: 1473-5.
  37. Terasaki PI, Cecka JM, Gjertson DW, Cho YW. Spousal and other living donor transplants. Clinical Transplants, 1997; 01 Jan 1997: 269-84.
  38. Collaborative Transplant Study Newsletter. Heidelberg University Institute of Immunology; 2004.
  39. Fuggle SV, Allen JE, Johnson RJ, et al. Factors affecting graft and patient survival after live donor kidney transplantation in the UK. Transplantation 2010; 89: 694-701.
  40. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney trans- plantation using both A2 and non-A2 living donors. Transplantation. 2003; 75: 971–977.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Cписок литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*